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Abstract: The ability to identify and treat cancer early can drastically improve patient survival outcomes. While 
much effort is placed on anti-cancer therapeutics, a developing area of interest is the identification of cancer 
biomarkers for the early detection of different types of cancer. Trefoil factors (TFFs) are a family of proteins 
whose known functions suggest that they may be major contributors to cancer; however, these proteins are 
understudied in a disease state like cancer. In this work, we identify expression of TFF1 among varying cancer 
types. We then investigate the correlation between varying levels of TFF1 expression and the aggressiveness of 
the cancer. Cell culture of seven different kinds of cancers was performed. Western blots were conducted, and the 
blots were probed for TFF1. After establishing TFF1 levels, we aimed to analyze cancer cell function through a 
series of cancer assays examining proliferation, viability, and migration. We hypothesized that there would be 
varying levels of TFF1 expression correlated to the functional characteristics of the cancer cells, and that 
increased levels of TFF protein would support a more aggressive cancer. The breast cell lines tested were the only 
lines to express TFF1 and were less aggressive than the lines with no expression. 
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Cancer is a detrimental disease associated 
with aging; as life expectancy rises so does the 
risk of getting cancer. Globally, an estimated one 
in three women and one in two men will develop 
cancer in their lifetimes1. Cancer is characterized 
by uncontrollable cell growth that gains resistance 
to death signals, increasing pro-survival 
mechanisms of the cancerous cell and its 
properties2. Although cancer treatments have 
caused survival rates to increase, there is a 
demand for viable biomarkers for the many types 
of different cancers. A viable biomarker is 
indicative to the presence of cancer within the 
body and helps diagnose patients promptly.  
Trefoil factors (TFFs) are secreted proteins 
that help in healing epithelial tissue in the 
stomach3, thus have the potential to be biomarkers 
in many types of cancers. The normal function of 
TFFs is to regulate cell growth and assist cells in 
recognizing environmental stress that leads to 
inflammation. While TFFs are an attractive cancer 
biomarker, further investigation of cancer cell 
function in the context of TFF expression could 
also provide information on the plausibility of 
TFFs as treatment targets. Further research on 
TFFs is required to understand their expression 
and function in cancerous cells. The need for this 
research is not only to better understand TFFs in  
 
cancers but hopefully to identify a new source of 
markers for detecting cancer in its earlier stages, 
and therefore mitigate aggressive and potentially 
intractable metastic disease.  
In this study, we aimed to identify the levels 
of TFF1 expression in cancerous cells that have 
not been investigated for the family of proteins. 
We then correlated the varying levels of 
expression to the aggressiveness of the cancer. 
We hypothesized that there would be varying 
amounts of TFF1 expression due to the functional 
characteristics of the cancer cells. We also 
expected that increased levels of TFF1 would be a 
form of support for a more aggressive cancer. We 
found that the breast cell lines tested were the 
only lines to express the protein and were actually 
less aggressive than the lines with no TFF1 
expression.  
LITERATURE REVIEW 
Cancer is one of the largest epidemics in our 
world. In 2012, an estimated 14 million new cases 
of cancer and 8.2 million cancer-related deaths 
were documented world-wide2. Early detection 
and prevention of cancer has become just as 
paramount a concern as treatment, leading many 
to investigate new possible biomarkers for the 
disease. Cancer markers are substances naturally 
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 produced by the body, and when cancer is present 
these substances are produced at different levels2. 
TFFs are proteins secreted by epithelial cells 
primarily for wound healing in mucosal 
membranes, which makes its investigation as a 
biomarker attractive3. The proteins are named 
after a trefoil motif structure composed of 
disulfide loops5. There are three TFFs: TFF1, 
TFF2 and TFF3. TFF1, previously known as pS2, 
was first found in breast cancer, and TFF2 was 
extracted and purified from the pancreas6-7. 
Intestinal trefoil factor, now TFF3 was later found 
in both intestines8. This family of proteins has 
similar characteristics but vary in expression and 
function throughout the body9.  
The stomach is the only organ in which all 
three TFFs are expressed9. TFF1 expression is 
highest in the stomach and colon, while TFF2 
levels are highest in the stomach, and TFF3 levels 
are highest in the colon9. Other studies have 
looked at particular parts of the body and cancer 
cells located within those parts (e.g., gastric and 
breast) to determine TFF expression11-20. Recent 
studies have found TFF expression may lead to 
detection of various cancers21-24. TFF proteins are 
gaining recognition as cancer biomarkers in the 
field. The purpose of this literature review is to 
investigate TFF expression in different cancers 
and identify their likelihood as biomarkers.  
Trefoil Factors in Gastric Cancer 
Gastric cancer is the fifth most common 
cancer world-wide, accounting for almost 1,000 
of the new cancer cases in 201210. There are 
known classic biomarkers for gastric cancer but 
TFFs may be novel markers for the disease11. 
TFF1 expression is essential for gastric mucosa 
cells to differentiate12. When expression of TFF1 
is low, gastric adenomas can develop and a 
percentage of the tumors can become cancerous12. 
Low expression of TFF1 in the gastric mucosa 
could show signs for early detection of stomach 
adenoma carcinoma, but the opposite could be 
true for TFF3. 
TFF3 expression levels are typically low in 
gastric mucosa, but it is overexpressed in gastric 
cancer13. High TFF3 expression could be an 
effective biomarker for gastric cancer. In one 
study, 90 gastric cancer patients provided blood 
and urine samples that were examined for TFF3 
levels14. TFF3 levels were significantly higher in 
the serum and urine of cancer patients compared 
to the healthy individuals. These higher levels 
correlated with the advancement of the stages as 
well as the distance of metastasis. The authors 
concluded that TFF3 serum could be a biomarker 
for gastric cancer in detecting tumor stages and in 
identifying metastases. Overexpression of TFF3 
in gastric cancer has led researchers to consider 
that it has potential as a cancer marker, and the 
same may be true for TFF215. 
TFFs appear to be regulated on their own, but 
in some cases other proteins or substances help 
mediate their regulation. Sp3 protein was found to 
be an essential binding partner to TFF2, which 
mediates the biological functions of the protein in 
gastric cancer cells15. Overexpression of the two 
proteins suppressed cell proliferation and induced 
apoptosis of the cancer cells and significantly 
lowered cell invasion as well. These findings 
showed that Sp3 is needed to regulate TFF2 and 
together their overexpression (or their absence) 
could make for cancer markers15.   
Trefoil Factors in Breast Cancer 
Breast cancer is the most common cancer 
among women and the second most common 
cancer world-wide10, and it is well established that 
TFFs are expressed in MCF-7 breast cancer cell 
lines16. In a study that used knockdown TFF1 in 
MCF-7 cells, the effects of estrogen with 
doxorubicin treatment were tested17. The cells that 
started with a low expression of TFF1 had 
upregulated expression after being transfected. 
The proteins expressed pro- or anti-apoptotic 
properties, which led the authors to the idea that 
TFF1 has a role in the apoptotic status of the cells. 
The authors made connections that estrogen 
inhibits the actions of doxorubicin and that TFF1 
can play a role in allowing estrogen to do this17. 
Kannan et al. used MCF-7 and T47D cells 
transfected with TFF3 to determine TFF function 
and relationship with estrogen18. TFF3 was 
identified as a novel growth factor in breast 
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 cancer. Forced expression of this gene enhanced 
oncogenesis. Estrogen regulates TFFs and 
protects MCF-7 breast cancer cells from death. 
Together, estrogen and TFF expression can be a 
viable biomarker for breast cancer17-18.  
Ahmed et al. investigated TFF3 expression in 
normal breast cancer cells, benign breast tumors 
and in situ carcinomas19. In the normal breast 
tissues, TFF3 protected the epithelial tissue, but 
TFF3 expression was lost in invasive breast 
cancers. TFF3 expression was also restricted at 
certain times during a woman’s menstrual cycle. 
TFF3 was found to have a negative relationship 
with tumor grade for the cancers studied, but 
could better differentiate the type of tumor. The 
authors found that TFF3 stimulates angiogenesis 
in the cancer cells. The authors also stated that in 
vitro studies of this kind would help back up their 
claim that TFF3 may be a prognosis marker. May 
and Westley evaluated TFF3 as a biomarker and 
noted the response of this protein in breast cancer 
cells20. Human TFF3 was transfected into breast 
cancer tissues from patients that underwent 
endocrine response therapy. Tumors with high 
TFF3 levels had evenly distributed expression 
compared to tumors with lower TFF3 levels, 
which had sparse expression. This pattern could 
be due to the amount of estrogen present in the 
body or the woman’s menstrual cycle as stated 
previously19. The authors concluded that TFF3 
expression might work as an independent 
predictive biomarker for estrogen and be specific 
and sensitive as a marker in breast cancer. 
Trefoil Factors in Other Cancers 
There are over 100 types of known cancers2, 
and only a few forms of cancer have been studied 
for TFF expression. Prostate cancer, endometrial 
adenocarcinoma (EAC), and lung adenocarcinoma 
have been investigated for TFF expression, 
including their possible roles as biomarkers for 
these specific cancers21. In prostate cancer, forced 
expression of TFF1 was shown to decrease E-
CADHERIN (protein) expression leading to an 
increase of metastases and invasion of the cancer 
cells, both in vivo and in vitro. In vivo, the cells 
invaded and metastasized at an increased rate. The 
authors concluded that overexpression of TFF1 
could be a biomarker for prostate cancer and 
determine tumor metastasis or tumor burden. In 
this study, E-CADHERIN transcription was 
mediated by TFF1; however, as stated before 
estrogen or estrogen receptor (ER) have different 
roles in mediating TFF expression21.  
Estrogen levels have been found to correlate 
with TFF levels in many breast cancer studies. 
Like in breast cancer, the combination of ER and 
TFF can make for a specific marker in uterine 
cancer22. In EAC it has been confirmed that high 
levels of ER lead to good prognosis for the 
cancer22. Mhawech et al. aimed to evaluate TFF3 
expression and prognosis as well as look at its 
relationship with ER22. High levels of TFF3 
corresponded with those of ER, providing 
evidence that TFF3 and ER lead to better tumor 
outcomes. TFF3 could possibly stand alone as a 
biomarker for EAC patients, but additional 
investigation is needed to support this. The 
authors suggested further research of knockdown 
TFF3 in EAC to determine its role in 
proliferation, migration and invasion of tumors 
and as a cancer marker22. Identified biomarkers 
for uterine cancer exist, but TFFs can be 
compared to the cancers to analyze their 
effectiveness and expression. 
Lung cancer is the deadliest and most 
common cancer worldwide, which compels the 
need for biomarkers for early onset detection.9. 
Wang et al. studied the expression of established 
biomarkers TTF-1, CK7, P63 and CK5/6 in lung 
adenocarcinoma and squamous cell carcinoma 
and compared their expression patterns to those of 
TFF323. In comparison to the established markers, 
TFF3 had a 90% expression pattern in lung 
adenocarcinoma. The authors found higher levels 
of TFF3 in the cancer cells, which varied in the 
amount of expression between the cell lines, and 
TFF3 played a role in differentiating the cells. 
Lastly, the authors concluded that TFF3 is all 
around “more sensitive” as a biomarker for all 
organs, not just specific organs compared to the 
established biomarkers23. This study showed that 
TFF3 has the potential of being a biomarker when 
compared to established markers.  
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 Conclusion 
Cancer treatment has progressed, allowing 
researchers and physicians to get the five-year 
survival rate up to 66%; yet, there is more that can 
be done to raise this percentage9. Earlier detection 
of the disease can lead to better prognosis, and 
lower the amount of cancer-related deaths. TFF 
proteins have the potential to be biomarkers in 
many types of cancers. The expression levels of 
these proteins could identify various cases of early 
onset cancer or the amplitude of metastases. Many 
cancers are left to be investigated for TFF 
expression. We looked at breast cell lines MCF-7, 
E-3, EWD-8, skin A375, lung A549, colon 
COLO205 and mast cell lines P815 for TFF1 
expression. We expected varying levels of TFF1 
expression correlated to the functional 
characteristics of the cancer cells, and that 
increased levels of TFF protein would support a 
more aggressive cancer. TFFs may be viable 
biomarkers that can aid in the early prognosis of 
cancer that in turn may lead to the use of less 
invasive and detrimental forms of cancer 
treatment. Further investigation of these proteins 
as biomarkers is also necessary.   
METHODS 
Cell Culture  
Breast MCF-7, E3 and EWD8, skin A549, 
lung A375, colon COLO205 and mast P815 cells 
were cultured in 10cm diameter dishes and T75 
cell culture flasks (VWR, Radnor, PA) 
Dulbecco’s Modified Eagle Medium (DMEM, 
Thermo Fisher Scientific, Waltham, MA). The 
culture medium was supplemented with 
(%volume) 10% equine and fetal bovine serum 
mixture (FBE from VWR), and 2mM L-
glutamine, 1mM sodium pyruvate, 0.01M 
HEPES, and 1 unit/mL penicillin/streptomycin 
mixture (all from Thermo Fisher Scientific). Cells 
were enzymatically passaged with trypsin-EDTA 
(Thermo Fisher Scientific) when the bottom of the 
plate was fully covered by the cancerous cells. 
Since trypsin passaging can epigenetically 
influence cells over many passages, low passage 
number samples were used from liquid nitrogen 
storage. 
Protein Isolation and Concentration 
Measurements 
Approximately 35000ml of cells from a 
passage were placed into six well plates and 
allowed to grow over 3 days. For cell lysis, plate 
was put on ice and 100µl of 1X Lysis Buffer (Cell 
Signaling Technology, Danvers, MA), with 
protease inhibitors leupeptin and orthovanadate, 
was added to each well. After lysis and of proteins 
into the buffer for 10-15min the mixture was 
centrifuged at 14,000xg for 10min to separate 
leftover cell/organelle membrane fractions from 
solubilized proteins.  The supernatant, which 
contains intracellular proteins like TFFs, was kept 
to measure protein concentration. A Nanodrop 
2000 device was used to measure protein 
concentrations from the samples.  
SDS-PAGE and Immunoblotting 
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by 
immunoblotting was conducted on cell lysates and 
replicated to detect TFF expression in the cells. 
Equal quantities of total protein from each sample 
were loaded based on Nanodrop concentration 
data. The gel tank was set up using a 1X Tris-
Glycine Running Buffer system. A size 
standardized ladder and samples were loaded into 
a 4%-20% polyacrylamide, Tris-Glycine gels and 
resolved according to manufacturer’s instructions 
(BIO-RAD, Hercules, CA). Once the proteins 
separated, the gel was transferred to a stable 
nitrocellulose blot using BIO-RAD’s Transblot 
Electrode apparatus according to manufacturer’s 
protocol. Using Ponceau S, we observed for equal 
loading in each blot. Next, a standard primary 
blocking buffer of Tris-Buffered Saline, 0.1% 
(v/v) Tween-20 (TBS-T), 5% (v/v) bovine serum 
albumin was used to block non-specific protein 
binding by incubating with the blots at ambient 
temperature for 1h with gentle agitation.  After 
blocking rabbit anti-human TFF1 (1:1000 dilution 
factor in block buffer; Cell Signaling Technology) 
was added to each blot, which were incubated 
overnight with gentle agitation at 4oC. The 
following day an anti-rabbit secondary antibody 
(1:5000 dilution; LI-COR Biosciences, Lincoln, 
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 NE) solution of TBS-T, 5% (v/v) non-fat dry milk 
was added to the blot after removing the primary 
and rinsing with TBS-T. Blots were incubated 
with the secondary antibody solution for 1h at 
ambient temperature with gentle agitation.  
Secondary incubation was followed by rinsing 
with TBS-T. The secondary antibody has a horse 
radish peroxidase (HRP) enzyme attached to it; 
therefore, the blot was developed using a 
chemiluminescent HRP substrate detection 
reagent (WesternSure, LI-COR) and scanned with 
the LI-COR cDigit device.  
Migration Assay and Daily Count  
A scratch test was conducted to assess the 
migration of each cell line. Approximately 
50000ml of cells was added to 10cm plate and 
allowed to settle and cover the plate. The cells 
were then scratched with a 200 L pipette tip, and 
pictures were taken over time. Images were taken 
daily until the scratch completely closed. ImageJ 
(NIH, Bethesda, MD) was used to obtain the 
surface area of the scratch from each image. Daily 
counts for every cell line was also done to assess 
growth rate, by adding 20µl of cells into 6-well 
plates and counting one well per day. Trypsin was 
added to lift the cells and then counted with Life 
Technologies Countess II (Carlsbad, CA).    
Statistical Analysis 
A qualitative approach was taken to observe 
for the presence of bands indicating the presence 
of TFF1 among each cell line. Descriptive 
statistics were used to compare TFF1 expression 
from cell type to cell type by taking the pixel 
density average of MCF-7 and using it to take a 
ratio for the other cell lines average expression. 
Using ImageJ the surface area was averaged from 
each scratch for each cell line.  
RESULTS 
After running Westerns blots, we found that 
only three of the seven cell lines tested expressed 
TFF1 (Fig. 1A) Equal loading of the protein was 
assured through Ponceau S staining (Fig. 1B). 
Breast MCF-7 was used as our positive control for 
TFF1 expression. Breast E3 and EWD8 cell lines 
also expressed the protein. MCF-7 on average 
expressed the highest amount of TFF. Cell line E3 
expressed the second highest amount of TFF and 
EWD8 expressed the lowest amount, yet the ratio 
was much smaller than 1 (MCF-7) for these cell 
lines (Fig 2). From the scratch tests MCF-7, E3 
and EWD8 appear to migrate the slowest (Fig. 3) 
E3 on average took eight days to close the scratch 
made, MCF-7 took an average of five days to seal 
the closure, and EWD8 averaged six days. Cell 
line A549 that did not express TFF1, on average 
closed the scratch in two days. Daily cell count 
for each cell type showed that MCF-7, E3 and 
EWD8 cell lines had lower proliferation rates 
compared to the cell lines that did not express 
TFF1. At the end of the six-day count cell 
concentration was 51,700 cells/mL for MCF-7, 
39,400 for E3 cells/mL and 2,090,000 cells/mL 
for EWD8 (Fig. 4).  
Figure 1. A) TFF expression is shown through 
Western blot. MCF-7 expressed the most protein 
overall. B) Ponceau S staining of the blots was done to 
ensure equal loading among each cell line.  
 
 
 
 
 
 
 
 
 
MCF-7 E3      EWD8  
A 
B 
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 Figure 2. Pixel density was taken from the blots. The values were averaged and a ratio was taken from the 
average of MCF-7 expression. E3 and EWD8 expressed TFF protein.
Figure 3. Cell migration over time is shown after scratch tests were performed. Three scratches were made in 
10ml petri dishes after the cells had completely covered the surface for each cell line expect P815 because of their 
floating properties. ImageJ was used to obtain the surface area of the scratches from each image. MCF-7, E3 and 
EWD8 appear to have migrated the slowest.
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 Figure 4. Daily count of each cell was done. Counting for every cell line was done by adding 20µl of cells into 6-
well plates and counting one well per day using the trypan blue exclusion method and a Life Technologies 
Countess II device. Cells that did not express TFF proliferated more than those who expressed it such as MCF-7, 
E3 and EWD8.
DISCUSSION 
Our results show that only three of the seven 
total cell lines tested had TFF1 protein expression 
including the positive control. We predicted that 
there would be varying levels of TFF1 among the 
cell lines because of their morphological 
characteristics. All three of our breast cell lines 
MCF-7, E3 and EWD8 expressed TFF1 protein; 
this may be due to their luminal breast cancer 
characteristics. TFFs are well known for being 
expressed in MCF-7 breast cancer cell lines3, and 
on average MCF-7 expressed the highest amount 
of TFF1. E3 expressed the second highest amount 
of TFF1, and EWD8 expressed the lowest 
amount. As previously stated estrogen appears to 
mediate TFF expression17-20. MCF-7 and cell lines 
E3 express estrogen receptor while EWD8 cell 
lines are estrogen-withdrawn cell lines27. This 
may explain why MCF-7 and E3 expressed more 
TFF1 than the EWD8s. EWD8 may be 
regenerating estrogen or have estrogen strands left 
over that would cause the low but present TFF1 
expression. Treating the cells with estrogen and 
progesterone may have significant changes on the 
cell’s TFF expression and is worth considering. 
Previous research has found that 
overexpression of TFFs can be used as a possible 
biomarker for certain cancers. We also 
hypothesized that the cancer would be more 
aggressive if more TFF1 was present (i.e., faster 
growth rate, faster scratch closure), but our 
current observations showed the opposite pattern. 
Further assays suggested that these cells grow as 
slow as the positive control (MCF-7) compared to 
the other cell lines, among which we did not 
detect any TFF1 expression. The cell lines 
expressing TFF1 on average took a longer time to 
close the scratch test. Daily counting provided 
more evidence that there were lower rates of 
proliferation on average in the breast cell lines. 
TFFs have been found to be biomarkers and to 
have oncogenic or tumor suppressing effects 
among many cancers10-13. Some have correlated 
high TFF expression with aggressive cancers 
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 across different phenotypes, thus indicating their 
promise as a cancer biomarker. There is also the 
possibility that TFF are a side effect from the 
cancer, rather than direct oncogenes, yet further 
research is required.  
A limitation to this study was only probing for 
one of the three TFF proteins. We plan to adjust 
our protocol in order to probe for the TFF2 and 
TFF3 antibodies. Our data suggested that the 
more TFF present the less aggressive the cancer 
suggesting it can be used as a possible target 
treatment for aggressive cancers. Next steps 
would be to treat one of the more aggressive cell 
lines, like lung A549 with recombinant TFF and 
observe for any changes in the cancers 
aggressiveness. Since cell lines MCF-7, E3 and 
EWD8 expressed TFF1, we also plan to use gene-
silencing techniques, such as siRNA transfection 
and/or CRISPR-Cas9, to edit the cells’ genomes 
and remove the TFF1 protein. Thus, we plan to 
observe what occurs in regards to the 
aggressiveness of the cancer in the absence of the 
specific TFF, in cell lines typically expressing the 
TFF. We would expect the treated lung A549 cell 
lines to become less aggressive, and the 
knockdown-TFF1 cell lines MCF-7, E3 and 
EWD8 to become more aggressive.   
We originally predicted that TFF1 expression 
would be associated with more aggressive cancer 
cells but found the opposite pattern. The cancer 
cell lines that expressed TFF1 were less 
aggressive than those that did not which implies 
that the loss of these proteins within these cancers 
would lead to a cancer that is more aggressive. 
While our results do not demonstrate what we 
initially hypothesized, it is important to note that 
TFFs may still be biomarkers for less aggressive 
cancer types. High expression levels of TFFs 
could allow for the detection of less aggressive or 
early stages of aggressive cancers. Based on these 
data and prospective clinical data what we would 
expect to see less aggressive breast cancers 
express higher levels of TFFs than more 
aggressive cancers. TFFs continue to be debated 
on whether they are tumor suppressors or 
oncogenes as well as varying levels working as 
biomarkers in many cancers, yet the proteins seem 
to have the potential to be viable cancer 
biomarkers in less aggressive cancer settings from 
our findings.   
Identification of cancer biomarkers is essential 
for the early detection of cancer to improve 
patient survival outcomes. Treatment and therapy 
is crucial in the fight against cancer, yet it comes 
with many discomforts. Biomarkers would allow 
for the early detection of the cancer that could 
possibly lead to less invasive and aggressive 
treatments. Further investigation would allow for 
the categorization of TFF1 in these cancers as 
oncogenic or tumor suppressors. TFF could also 
possibly work as a treatment to suppress cancers.  
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